Dimethyl Myleran Therapy for Cancer
Author Information
Author(s): Peter Clifford, R. A. Clift, A. G. Khan, G. M. Timmis
Primary Institution: King George VI Hospital, Nairobi, Kenya and the Chester Beatty Research Institute, Institute of Cancer Research: Royal Cancer Hospital, London
Hypothesis
Can dimethyl Myleran combined with abdominal aortic occlusion effectively treat advanced malignant diseases of the head and neck?
Conclusion
Dimethyl Myleran therapy resulted in marked tumor regression in some patients, but also caused significant toxicity.
Supporting Evidence
- Eight out of the fifteen cases treated had marked tumour regression.
- One patient was discharged histologically free of disease.
- Dimethyl Myleran was found to be free from neurological toxicity.
- Common complications included bucco-labial mucositis, alopecia, and thrombocytopenia.
Takeaway
Doctors tried a new cancer treatment called dimethyl Myleran, and it helped some patients feel better, but it also made them very sick.
Methodology
Patients received dimethyl Myleran intravenously after abdominal aortic occlusion, with varying doses and occlusion times.
Limitations
The study had a small sample size and significant toxicity was observed.
Participant Demographics
Patients had advanced malignant diseases, including anaplastic carcinoma and plasmacytoma.
Want to read the original?
Access the complete publication on the publisher's website